Opendata, web and dolomites

IL7RsignaTHER SIGNED

Antibody-based IL-7R targeted therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IL7RsignaTHER project word cloud

Explore the words cloud of the IL7RsignaTHER project. It provides you a very rough idea of what is the project "IL7RsignaTHER" about.

relapses    peripheral    minimize    malignancies    adults    considerably    cancer    severe    free    solid    chemotherapy    obvious    cell    lymphoblastic    detrimental    strategies    surface    risk    aggressive    efficient    expression    frequent    leukemia    malignancy    80    bowel    colorectal    hematological    il7signeture    cancers    inflammatory    prognosis    lymphocytic    conventional    complications    generate    cells    bladder    diabetes    plays    ectopic    breast    axis    children    7r    disease    biopharmaceuticals    agent    data    outcome    lymphoma    remission    rheumatoid    antibody    indications    worse    preliminary    therapies    childhood    lymphoid    monoclonal    40    explore    intensive    il    648455    pathological    regimens    multiple    diseases    erc    therapeutic    remarkable    lung    commercialize    scenario    adjusted    extends    autoimmune    treatment    leukemic    signaling    dependence    melanoma    acute    broad    grant    hodgkin    unmet    alive    arthritis    glioblastoma    consolidator    market    chronic    innovative    sclerosis    mediated    improvement    cog    pediatric    dismal    led   

Project "IL7RsignaTHER" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 150˙000.00

Map

 Project objective

Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years. However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens used are often associated with long-term, severe complications. In adults, the scenario is considerably worse: only 30–40% of the cases achieve long-term remission. Therefore, there is an obvious unmet need, and a major challenge, to develop novel, more efficient therapeutic strategies that specifically target the leukemic cells, minimize the detrimental side effects associated with conventional therapies and improve overall treatment outcome. Based on exciting and robust preliminary data from our ERC Consolidator Grant IL7sigNETure (CoG-648455), we now propose to explore the dependence of ALL cells on IL-7/IL-7R-mediated signaling and the broad expression of IL-7R on the surface of ALL cells to develop and commercialize novel monoclonal antibody-based biopharmaceuticals that we will generate targeting the IL-7/IL-7R axis for treatment of this malignancy. Our innovative therapeutic strategies have significant market potential that extends beyond ALL. Other possible indications include other lymphoid malignancies (Hodgkin's lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia), solid cancers with ectopic expression of IL-7R (including melanoma, breast, lung, bladder and colorectal cancer, or glioblastoma), and autoimmune and chronic inflammatory diseases (diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease) in which the IL-7/IL-7R axis plays a pathological role.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IL7RSIGNATHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IL7RSIGNATHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More